FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916895013> ?p ?o ?g. }

• W2916895013 endingPage "4699" @default.
• W2916895013 startingPage "4685" @default.
• W2916895013 abstract "Breast cancer brain metastases (BM) affect younger women disproportionally, including those lacking estrogen receptor (ER), progesterone receptor, and HER2 (known as triple-negative breast cancer; TNBC). Previous studies in preclinical models showed that pre-menopausal levels of estradiol (E2) promote TNBC-BM through incompletely understood mechanisms involving reactive astrocytes. Herein, a novel mechanism involving E2-dependent upregulation of brain-derived neurotrophic factor (BDNF) in astrocytes, and subsequent activation of tumor cell tropomyosin kinase receptor B (TrkB), is identified. E2 increased experimental BM of TNBC 4T1BR5 and E0771 cells by 21 and 3.6 fold, respectively, compared to E2-depleted mice. ERα+ reactive astrocytes were found at early and late stages of BM, and E2 upregulated BDNF in ER+ reactive astrocytes in vitro and in vivo. TrkB was expressed in TNBC brain-trophic cell lines, BM-patient-derived xenografts, and breast cancer BM. Conditioned media from E2-treated astrocytes (CM-E2) activated TrkB and downstream AKT, ERK, and PLC-γ signaling in TNBC cells, increasing their invasiveness and tumor-initiating capability in vitro. The promotion of BM by E2-activated astrocytes was found to be more complex, involving feedback loops and other receptor tyrosine kinases. In 4T1BR5 cells, there was a positive feedback loop whereby astrocytic BDNF induced cancer cell BDNF translation. Upregulation of cancer cell BDNF was required to promote full invasiveness of 4T1BR5 in response to CM-E2, and was observed in brain metastatic cells in E2-treated mice in vivo. Moreover, the non-competitive BDNF/TrkB inhibitor ANA-12 reduced E2-induced 4T1BR5 BM to levels similar to OVX mice. BDNF also activated EGFR in TrkB+EGFR+ TNBC cells, suggesting that E2 action through astrocytes activates redundant pathways promoting BM. These findings have important therapeutic implications, as they provide a rationale to use E2-depletion therapies or TrkB inhibitors to prevent or delay development of BM in younger women." @default.
• W2916895013 created "2019-03-02" @default.
• W2916895013 creator A5001562050 @default.
• W2916895013 creator A5009428042 @default.
• W2916895013 creator A5011696718 @default.
• W2916895013 creator A5012158652 @default.
• W2916895013 creator A5035391817 @default.
• W2916895013 creator A5069533295 @default.
• W2916895013 creator A5077822199 @default.
• W2916895013 creator A5082848118 @default.
• W2916895013 date "2019-02-22" @default.
• W2916895013 modified "2023-10-11" @default.
• W2916895013 title "Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases" @default.
• W2916895013 cites W1527035699 @default.
• W2916895013 cites W1550159293 @default.
• W2916895013 cites W1892553999 @default.
• W2916895013 cites W1945000986 @default.
• W2916895013 cites W1967894062 @default.
• W2916895013 cites W1977573757 @default.
• W2916895013 cites W1981672008 @default.
• W2916895013 cites W1999890575 @default.
• W2916895013 cites W2004065307 @default.
• W2916895013 cites W2004107819 @default.
• W2916895013 cites W2004904601 @default.
• W2916895013 cites W2005830551 @default.
• W2916895013 cites W2006154529 @default.
• W2916895013 cites W2017472087 @default.
• W2916895013 cites W2021497853 @default.
• W2916895013 cites W2023724297 @default.
• W2916895013 cites W2025849462 @default.
• W2916895013 cites W2026987067 @default.
• W2916895013 cites W2037200077 @default.
• W2916895013 cites W2039376139 @default.
• W2916895013 cites W2042736191 @default.
• W2916895013 cites W2042905219 @default.
• W2916895013 cites W2051556001 @default.
• W2916895013 cites W2052253951 @default.
• W2916895013 cites W2052912902 @default.
• W2916895013 cites W2056139665 @default.
• W2916895013 cites W2058689904 @default.
• W2916895013 cites W2063083613 @default.
• W2916895013 cites W2063252423 @default.
• W2916895013 cites W2063849763 @default.
• W2916895013 cites W2077113617 @default.
• W2916895013 cites W2081721009 @default.
• W2916895013 cites W2084188625 @default.
• W2916895013 cites W2086975209 @default.
• W2916895013 cites W2088954638 @default.
• W2916895013 cites W2095184120 @default.
• W2916895013 cites W2096027508 @default.
• W2916895013 cites W2096407616 @default.
• W2916895013 cites W2096661713 @default.
• W2916895013 cites W2098634708 @default.
• W2916895013 cites W2099540110 @default.
• W2916895013 cites W2115727543 @default.
• W2916895013 cites W2116975728 @default.
• W2916895013 cites W2119184935 @default.
• W2916895013 cites W2119679649 @default.
• W2916895013 cites W2123460738 @default.
• W2916895013 cites W2126799977 @default.
• W2916895013 cites W2139085578 @default.
• W2916895013 cites W2147548562 @default.
• W2916895013 cites W2161849165 @default.
• W2916895013 cites W2168143678 @default.
• W2916895013 cites W2169465106 @default.
• W2916895013 cites W2174136167 @default.
• W2916895013 cites W2273567156 @default.
• W2916895013 cites W2298328682 @default.
• W2916895013 cites W2326384180 @default.
• W2916895013 cites W2395872025 @default.
• W2916895013 cites W2395943362 @default.
• W2916895013 cites W2524674719 @default.
• W2916895013 cites W2608725311 @default.
• W2916895013 cites W2765527092 @default.
• W2916895013 cites W2806597619 @default.
• W2916895013 doi "https://doi.org/10.1038/s41388-019-0756-z" @default.
• W2916895013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6565485" @default.
• W2916895013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30796353" @default.
• W2916895013 hasPublicationYear "2019" @default.
• W2916895013 type Work @default.
• W2916895013 sameAs 2916895013 @default.
• W2916895013 citedByCount "60" @default.
• W2916895013 countsByYear W29168950132019 @default.
• W2916895013 countsByYear W29168950132020 @default.
• W2916895013 countsByYear W29168950132021 @default.
• W2916895013 countsByYear W29168950132022 @default.
• W2916895013 countsByYear W29168950132023 @default.
• W2916895013 crossrefType "journal-article" @default.
• W2916895013 hasAuthorship W2916895013A5001562050 @default.
• W2916895013 hasAuthorship W2916895013A5009428042 @default.
• W2916895013 hasAuthorship W2916895013A5011696718 @default.
• W2916895013 hasAuthorship W2916895013A5012158652 @default.
• W2916895013 hasAuthorship W2916895013A5035391817 @default.
• W2916895013 hasAuthorship W2916895013A5069533295 @default.
• W2916895013 hasAuthorship W2916895013A5077822199 @default.
• W2916895013 hasAuthorship W2916895013A5082848118 @default.
• W2916895013 hasBestOaLocation W29168950131 @default.
• W2916895013 hasConcept C104317684 @default.

• next